GLUE · Monte Rosa Therapeutics, Inc.
Market Cap
$1.22B
Shares
85.31M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.38
Open$14.29
Day$13.37–14.30
52W close$4.80–25.31
Avg vol 30d1.4M
Short int17.5M · 20.5% float · 14.0d
Short vol31%
Last earningsMar 17, 2026
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−32%
below
RSI (14)
29
oversold
MACD trend
Positive
52-week position
42%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−24%
trailing
YTD return
−15%
this year
Relative strength
−38%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +29 funds added
Insider flow
Distributing
Net -$451.3K over 90 days · 100% sells
Short interest
Rising
20.46% of float · ▲ +6.1% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+64%
Y/Y
Free cash flow
$-27.5M
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−32%
Bearish
RSI (14)
29
Neutral
MACD trend
Positive
Bullish
52-week position
42%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $20 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+2% holders QoQ · +29 funds added
Insider flow
Distributing
Net -$451.3K over 90 days · 100% sells
Short interest
Rising
20.46% of float · ▲ +6.1% MoM · 14.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $13 · 42%
Range high $25
vs 200-day avg -28%
vs 50-day avg -32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filingsFigures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLUE
this stock
Monte Rosa Therapeutics, Inc.
|
$1.22B | -14.7% | +63.5% | — | 20.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLUE | -6.4% | -19.0% | -24.2% | -19.0% | -14.7% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -6.9% | -22.0% | -37.7% | -22.0% | -27.5% |
Key facts
CIK
1826457
CUSIP
61225M102
13F (30d)
176 filings
173 filers
Visit website
Investor relations